Pacific Biosciences Of California (PACB) Operating Leases (2019 - 2026)

Pacific Biosciences Of California's Operating Leases history runs 8 years deep, the most recent figure standing at $59.0 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 16.89% year-over-year to $59.0 million in Q1 2026; TTM through Mar 2026 was $59.0 million, a 16.89% increase from a year earlier, with the FY2025 full-year figure at $56.6 million, up 279.46% from the prior year.
• Operating Leases advanced to $59.0 million in Q1 2026 per PACB's latest filing, from $56.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $59.0 million in Q1 2026 and bottomed at $14.9 million in Q4 2024.
• The 5-year median for Operating Leases is $40.0 million (2022), against an average of $38.7 million.
• Across the five-year window, Operating Leases plunged 52.81% in 2024 and surged 279.46% in 2025, its largest moves.
• Year by year, Operating Leases stood at $41.1 million in 2022, then declined by 23.04% to $31.6 million in 2023, then plunged by 52.81% to $14.9 million in 2024, then jumped by 279.46% to $56.6 million in 2025, then gained by 4.26% to $59.0 million in 2026.
• Per Business Quant, the three latest PACB Operating Leases figures stand at $59.0 million (Q1 2026), $56.6 million (Q4 2025), and $54.3 million (Q3 2025).